Impact of Weight Loss Surgery on Type 2 Diabetes Management
Study Overview
A five-year clinical study involving patients with type 2 diabetes and a body mass index (BMI) ranging from 27 to 43 indicates that weight loss surgery may be more effective than medication alone. Bariatric surgery, designed for individuals with obesity, reduces stomach size through methods such as gastric banding, which divides the stomach and reroutes the small intestine.
Study Population and Methodology
The study included 150 obese patients diagnosed with type 2 diabetes, selected based on specific criteria: ages between 20 and 60 years, a glycated hemoglobin level of seven or higher, and a BMI between 27 and 43. After being informed about the study, all participants provided voluntary informed consent. They were then randomly assigned to one of three groups: intensive medical treatment, intensive medical treatment combined with gastric bypass, or sleeve gastrectomy.
Initial Findings
The initial analysis, conducted three years post-randomization, revealed that patients who underwent bariatric surgery exhibited better glycemic control compared to those receiving solely medical therapy. Both gastric bypass and sleeve gastrectomy effectively achieved glycemic control (defined as a glycated hemoglobin level of 6% or lower), decreased cardiovascular risk, and enhanced overall quality of life.
Five-Year Follow-Up Analysis
A subsequent article published in the New England Journal of Medicine presented a five-year follow-up analysis of the same cohort, focusing on the long-term safety and efficacy of bariatric surgery for individuals with type 2 diabetes. Out of the original 150 patients, 134 (89%) participated in the follow-up. At the study’s start, the average age was 49 years, with a BMI of 37 and an average glycated hemoglobin level of 9.2%. Additionally, 44% of participants were on insulin at baseline.
The findings five years after surgery were promising, with 14 of 49 patients (29%) in the gastric bypass group and 11 of 47 patients (23%) in the sleeve gastrectomy group achieving a glycated hemoglobin level of 6.0% or less. In contrast, only 2 of 38 patients (5%) in the medical therapy group reached this target.
Weight Loss and Other Health Improvements
The surgical groups also demonstrated significant weight loss, with reductions of 23% for gastric bypass, 19% for sleeve gastrectomy, and 5% for the medical therapy group. Other improvements included reductions in triglyceride levels (−40%, −29%, and −8%, respectively), increases in high-density lipoprotein cholesterol (32%, 30%, and 7%), and a decrease in insulin usage (−35%, −34%, and −13%). Quality of life measures also improved, with general health scores increasing by 17, 16, and 0.3 for the respective groups. However, no significant differences in blood pressure or low-density lipoprotein cholesterol levels were noted among the groups.
Conclusion: Surgery vs. Medication
This study supports the notion that bariatric surgery, when combined with medication, yields favorable outcomes for patients managing type 2 diabetes. Key benefits include improved blood sugar control, significant weight loss, reduced reliance on diabetic medications, and enhanced quality of life compared to those receiving only medication therapy.
Reference
1. Shauer PR, Bhatt DL, Kirwin JP, et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. The New England Journal of Medicine. February 16, 2017. doi: 10.1056/NEJMoa1600869
Relevant Topics
– Endurance Exercise and Type 2 Diabetes
– Is Dark Chocolate Good for Diabetics?
– Stem Cell Therapy for Type 1 Diabetes
– How Do Midday Naps Affect Glycemic Control in Type 2 Diabetes?
– Impact of Fruit Consumption on Diabetes Risk
– Benefits of Ubiquinol Supplements for Type 2 Diabetes
– Bread-Making Techniques to Lower Your Risk of Diabetes